129 related articles for article (PubMed ID: 37258313)
1. Prostate-specific antigen screening for prostate cancer in countries with publicly funded health insurance.
Takahashi T
Public Health; 2023 Nov; 224():e2-e3. PubMed ID: 37258313
[No Abstract] [Full Text] [Related]
2. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
3. Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed.
Carter HB
Oncology (Williston Park); 2014 Feb; 28(2):155-6. PubMed ID: 24701706
[No Abstract] [Full Text] [Related]
4. Prostate Cancer Screening.
Dunn MW
Semin Oncol Nurs; 2017 May; 33(2):156-164. PubMed ID: 28343840
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
6. Should you skip your PSA test? The science is uncertain for now, so arm yourself with deep knowledge of the pros and cons of prostate cancer screening.
Harv Mens Health Watch; 2012 Oct; 17(3):1, 7. PubMed ID: 23175860
[No Abstract] [Full Text] [Related]
7. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials.
Goodwin JS; Tan A; Jaramillo E; Kuo YF
J Natl Cancer Inst; 2013 May; 105(10):743-5. PubMed ID: 23459245
[TBL] [Abstract][Full Text] [Related]
8. Determinants of prostate specific antigen screening test uptake in an urban community in North-Central Nigeria.
Bello JO; Buhari T; Mohammed TO; Olanipekun HB; Egbuniwe AM; Fasiku OK; Wasiu R
Afr Health Sci; 2019 Mar; 19(1):1665-1670. PubMed ID: 31148996
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Screening.
Catalona WJ
Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
[TBL] [Abstract][Full Text] [Related]
10. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening for men aged 75 to 84 years in New South Wales.
Carmichael LK; Goldsbury DE; O'Connell DL
Aust N Z J Public Health; 2013 Oct; 37(5):492-4. PubMed ID: 24090337
[No Abstract] [Full Text] [Related]
12. Individualizing PSA Monitoring Among Older Prostate Cancer Survivors.
Shi Y; Fung KZ; John Boscardin W; Ngo S; Freedland SJ; Wong ML; Walter LC
J Gen Intern Med; 2018 May; 33(5):602-604. PubMed ID: 29417461
[No Abstract] [Full Text] [Related]
13. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
14. Public health perspective on prostate-specific antigen screening: Implications of overdiagnosis and differences in health insurance systems across countries.
Takahashi T
J Med Screen; 2023 Mar; 30(1):49-50. PubMed ID: 36413434
[No Abstract] [Full Text] [Related]
15. Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
Hongo F; Okihara K; Kitamura K; Fujihara A; Yamada Y; Shiraishi T; Konishi E; Ukimura O
Int J Urol; 2019 Aug; 26(8):827-832. PubMed ID: 31183899
[TBL] [Abstract][Full Text] [Related]
16. Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?
Sugimoto M; Kakehi Y
Asian J Androl; 2012 Jul; 14(4):522-4. PubMed ID: 22751444
[No Abstract] [Full Text] [Related]
17. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
18. Prostate cancer: Melbourne consensus-noble but misguided.
Ahmed HU
Nat Rev Urol; 2014 May; 11(5):250-1. PubMed ID: 24662731
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening in Portugal: prevalence and perception of potential benefits and adverse effects.
Braga R; Costa AR; Pina F; Moura-Ferreira P; Lunet N
Eur J Cancer Prev; 2020 May; 29(3):248-251. PubMed ID: 31651568
[TBL] [Abstract][Full Text] [Related]
20. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
